The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

Inclusion Criteria: * Adult male patients with coronary artery disease (CAD) (one to three vessel diseased). * Stable cardiac status at least 3 months after percutaneous coronary intervention (PCI). * No change in cardiac medications for 4 weeks prior to enrollment. * Testosterone \< 300 ng/dl or free testosterone \< 5.0 ng/dl or bioavailable testosterone \< 150 ng/dl. * Sex Hormone Binding Globulin (SHBG) \< 7nmol/liter and Free Testosterone \< 50pg/dl * Prostate Specific Antigen (PSA) \< 2.5 ng/mL or 2.6-3.7ng/mL with a negative prostate biopsy within the last 6 months and pathology report available for investigator's review. * Subgroup of diabetics with well to moderately controlled diabetes (defined by a HgbA1c of \< 9mg/dL. Exclusion Criteria: * Hematocrit greater than 50%. * Severe hypertension (exhibit systolic blood pressure \>180mmHg and diastolic blood pressure \>110 mmHg at baseline visit or a have a history of malignant hypertension. * Significant cardiac arrhythmia (supraventricular tachycardia \[SVT\] or ventricular tachycardia with heart rate exceeding 110 beats per minute at Visit 1). * ECG abnormalities precluding ST segment analysis on treadmill, or inability to walk on treadmill. * Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer, benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder). * Neurological or psychiatric disorder that would compromise the patient's ability to give informed consent or adhe…